Pramipexole is a Medicine belongs to Antiparkinsonian Drugs group whose information about Brand can be referenced from   Book : Martindale    Page : 912   Edition : 38  

  ►   Brandname : Mirapexin, Mirapex, Sifrol, Pramip, BI-Sifrol
  ►  Strength : Tablet with 0.125 mg.  Tablet with 0.25 mg.  Tablet with 0.75 mg.  Tablet with 1 mg.  Tablet with 1.5 mg.  Extended- release tablets with 0.375 mg.  Extended- release tablets with 0.75 mg.  Extended- release tablets with 1.5 mg.  Extended- release tablets with 3.0 mg.  Extended- release tablets with 4.5 mg. 

Reference of this Medicine for its Strength can be taken from   Book : Basic & Clinical pharmacology    Page : 498   Edition : 12  
A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : Oral
Reference :-   Book : Martindale    Page : 911   Edition : 38  

Dosing of Medicine differ in Adult & Pediatrics ↓

Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 Parkinson’s disease Oral Tablet The dose of pramipexole should be increased gradually and the dose of levodopa gradually reduced during the dosetitration and maintenance phases until an optimum response is achieved. The initial dose of pramipexole hydrochloride is 125 micrograms three times daily increased to 250 micrograms three times daily in the second week and then to 500 micrograms three times daily in the third week according to response. Thereafter the daily dose may be increased if necessary by 750 micrograms at weekly intervals to a maximum of 4.5 mg daily. The dosage should be reduced in patients with renal impairment. If it is necessary to stop pramipexole therapy, it should be withdrawn gradually.
2 Restless legs syndrome Oral Tablet Pramipexole is also given as a single daily dose, 2 to 3 hours before bedtime, in the treatment of restless legs syndrome. The initial dose is 125 micrograms daily. This may be increased if necessary after 4 to 7 days to 250 micrograms daily. Subsequent doses may be increased if necessary by 250 micrograms every 4 to 7 days to a maximum of 750 micrograms daily. Response to therapy should be evaluated after 3 months; if treatment is interrupted for more than a few days, it should be restarted at 125 micrograms daily, and then increased, if required, as described above. For this indication, pramipexole may be withdrawn without gradual tapering of the dose.

Ref :-  Book : Martindale    Page : 911   Edition : 38  

Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  

Ref :- Book :    Page :    Edition :   
►  Side Effect : Somnolence, Dizziness, Hallucinations, Dream disorder, Asthenia, Amnesia, Orthostatic hypotension, Extrapyramidal movements
Ref :-   Book : Principle of Pharmacology (The Pathophysiologic Basis of Drug Therapy)    Page : 202   Edition : 3.  

►  Drug Interaction : Drug interaction of Pramipexole is with , Phenothiazines, Macrolide antibacterials,  Butyrophenone, Thioxanthenes , Metoclopramide , Memantine hydrochloride , Cimetidine , Octreotide
Ref :-   Book : Martindale    Page : 899, 912   Edition : 38.  

  ►    Mechanism of Drug Drug Interaction :  Cimetidine is reported to reduce the renal clearance of pramipexole. Caution is advised when other sedating drugs or alcohol are used with pramipexole because of possible additive effects and the risk of precipitating sudden onset of sleep. Dopamine antagonists such as the phenothiazines, butyrophenones, thioxanthenes, and metoclopramide might be expected to reduce the prolactin-lowering and the antiparkinsonian effects of pramipexole. Memantine may enhance the effects of pramipexole. Stimulants of gastrointestinal motility such as macrolide antibacterials or octreotide can increase the bioavailability of pramipexole.
Ref :-   Book : Martindale    Page : 899, 912   Edition : 38.  

►  Contraindication : Concomitant use of other sedating medications
Ref :-   Book : Principle of Pharmacology (The Pathophysiologic Basis of Drug Therapy)    Page : 202   Edition : 3.  
  ►  Mechanism of Action :   It is a non-ergot dopamine agonist, bind to and activate postsynaptic dopamine receptors directly.
Ref :-   Book : Martindale    Page : 898   Edition : 37.  

Pathway of DIETARY Product

​   ► Act.Comp / Nutrient / Food / Herb as follows :- Ginkobiloba i.e.Silver apricot i.e.balkuwari with Another pathway.   Fava beans i.e. bakla with same compound.  

  ►  Pathway with its reference as follows :-
  • Fava beans rich in levo-dihydroxyphenylalanine(L-Dopa) the precursor of dopamine. --- ( Mehran S.M., Mohseni. "Simultaneous Determination Of Levodopa And Carbidopa From Fava Bean, Green Peas And Green Beans By High Performance Liquid Gas Chromatography". JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH (2013): n. pag. Web. 10 Nov. 2016. )
  • Increase blood circulation in the brain --- (Edelberg, D. (2016). The new age of nutritional and herbal remedies. New Zealand. )

  •   ►  URL --
  • .
  • .

  • DIETARY Substance Interactions

    ​   ► This Medicine interact with :- NA

    ContraIndication DIETARY Substance

    ​   ► This Medicine contraindicate with :- AGNUS CASTUS I.E. NIRGANDHI with Nirgandhi interact with dopamine agonist drug.   ALCOHOL with It can increase the amount of drowsiness caused by the drug ..  

      ►  Reference :-
  • Driver, S. (2009). Stockleys Herbal Medicines Interactions. Royal pharmaceutical Society of Great Britain: Pharmaceutical press.
  • Gaby, A. (2006). A–Z Guide to Drug-Herb-Vitamin Interactions. 2nd ed. New York: Three Rivers Press

  •   ►  URL --

    ►   Route of Elimination :   Renal
    Ref :-   Book : Martindale    Page : 899   Edition : 37.  

    ►    Plasma Half-life :   Min value :-   8 ,    Max value :-   12 hours.  
    Ref :-   Book : Martindale    Page : 912   Edition : 38.  

    ►    Peak Plasma Concentration :   Min value :-   NA    Max value :-   NA